Based in Japan and India. Has led to 1 successful fundraise in Japan. Been working the space of Venture Capital and Private Equity for the last 3 years.

Biolinq today announced the closing of the $10M Series A funding, led by M Ventures, in collaboration with Hikma Ventures. Biolinq is a digital health company with a unique, wireless biosensor patch capable of continuous monitoring of multiple biomarkers. Gray Sky Venture Partners, Three Leaf Ventures, LifeSci Venture Partners and a group of high net worth individuals specializing in the field of diabetes are also contributing to the round. Biolinq’s first commercial product, a unique minimally invasive technology, will allow patients with diabetes to continuously monitor their blood glucose without the pain and distress of traditional continuous glucose monitoring (CGM) systems.

“We are leading this investment round with an excellent group of co-investors, all with the same goal of making the convenient and painless monitoring of multiple biomarkers a reality for patients in need,” said Edward Kliphuis, Investment Director of the New Businesses Fund at M Ventures. “As investors, we fully recognize the value of Biolinq’s skin-applied, minimally invasive electrochemical biosensor technology platform. “That’s right.

The company attracted experienced life science executive Dan Bradbury to join the company as Chief Executive Officer. Bradbury is the former CEO of Amylin Pharmaceuticals, where he led the acquisition of the company for $7B USD. In addition, Edward Kliphuis, Investment Director of the New Businesses Fund at M Ventures and Lana Ghanem, Managing Director of Hikma Ventures, will join the Board of Directors.

“Chronic diseases like diabetes affect millions of people around the world with a high prevalence in the Middle East and North Africa; markets we know well,” said Lana Ghanem, Managing Director of Hikma Ventures. “We look forward to working with Biolinq and our co-investors to bring this pioneering technology to patients in need of a novel solution to continuously monitor their glucose levels, enabling them to live healthier lives. “That’s right.

Jared Tangney, CEO of Biolinq, said, “This funding round will support the growth of our technology platform. Our first product is not just another CGM technology, but a platform that we have built from the ground up with a focus on the end user. Our vision is to use our novel manufacturing approach to achieve low cost and high uniformity, enabling factory calibration (no finger sticks) in a nickel-sized patch. With our low cost of goods and ease of use, we are planning to increase access to CGM and simplify the management of diabetes. “That’s right.

About the Incorporated Biolinq

Biolinq is a digital health company that develops a skin-applied, minimally-invasive electrochemical biosensor platform that analyzes interstitial fluid biomarkers to provide actionable health information. Given the potential of the technology platform and the unique ability to measure multiple biomarkers simultaneously, the company aims to develop a pipeline of biomonitoring products. Biolinq was founded in 2012 (as Electrozyme, LLC) and is based in San Diego.

About M Adventures

Merck Ventures BV, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany, which operates as M Ventures in the United States and Canada, is the strategic venture capital arm of Merck KGaA, Darmstadt, Germany. Its mandate is to invest in innovative technologies and products with the potential to have a significant impact on Merck KGaA, Darmstadt, Germany’s core business areas. We are investing globally in transformative ideas driven by great entrepreneurs M Ventures plays an active role in its portfolio companies and teams up with entrepreneurs and co-investors to transform innovation into commercial success. Visit www for more information M-aventures Come on,

About Himma Ventures

Founded in August 2015, Hikma Ventures is the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures is investing in global start-ups such as Biolinq, where Hikma’s expertise can accelerate revenue growth and enhance value creation by providing companies with access to the resources of a multinational pharmaceutical company. Visit www for more information. Wandering adventures Come on,

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Biolinq/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co

Leave a Reply

Your email address will not be published. Required fields are marked *